Lazard Asset Management LLC reduced its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 21.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,622,280 shares of the medical research company's stock after selling 712,189 shares during the quarter. Lazard Asset Management LLC owned about 1.44% of IQVIA worth $515,302,000 at the end of the most recent reporting period.
Other hedge funds also recently added to or reduced their stakes in the company. Synergy Asset Management LLC acquired a new position in shares of IQVIA in the 4th quarter valued at $33,000. GKV Capital Management Co. Inc. purchased a new stake in shares of IQVIA during the 4th quarter worth about $39,000. Lee Danner & Bass Inc. acquired a new stake in IQVIA in the fourth quarter valued at approximately $44,000. Zions Bancorporation N.A. raised its position in IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after acquiring an additional 85 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of IQVIA in the fourth quarter worth approximately $60,000. 89.62% of the stock is owned by institutional investors and hedge funds.
IQVIA Price Performance
Shares of IQVIA stock traded down $1.31 during trading on Thursday, reaching $140.51. The company's stock had a trading volume of 2,595,876 shares, compared to its average volume of 1,506,384. The company has a market capitalization of $24.31 billion, a P/E ratio of 18.73, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34. IQVIA Holdings Inc. has a 12-month low of $135.97 and a 12-month high of $252.88. The business has a 50 day moving average price of $161.62 and a 200-day moving average price of $187.11. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.
IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.63 by $0.07. The company had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The firm's revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period in the prior year, the business posted $2.54 earnings per share. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on the stock. UBS Group decreased their target price on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $260.00 to $160.00 in a research report on Friday, April 25th. StockNews.com cut shares of IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Citigroup cut their price target on IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Finally, Barclays dropped their target price on IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 7th. Eight research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $230.76.
Read Our Latest Stock Report on IQV
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read More
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
